West Pharmaceutical Services (WST) EBIAT (2016 - 2025)
Historic EBIAT for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $140.0 million.
- West Pharmaceutical Services' EBIAT rose 294.12% to $140.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $491.7 million, marking a year-over-year decrease of 158.13%. This contributed to the annual value of $492.7 million for FY2024, which is 1697.0% down from last year.
- Per West Pharmaceutical Services' latest filing, its EBIAT stood at $140.0 million for Q3 2025, which was up 294.12% from $131.8 million recorded in Q2 2025.
- In the past 5 years, West Pharmaceutical Services' EBIAT ranged from a high of $188.5 million in Q2 2022 and a low of $89.8 million during Q1 2025
- For the 5-year period, West Pharmaceutical Services' EBIAT averaged around $141.9 million, with its median value being $140.0 million (2023).
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 11336.57% in 2021, then tumbled by 3132.12% in 2022.
- West Pharmaceutical Services' EBIAT (Quarter) stood at $147.7 million in 2021, then crashed by 30.26% to $103.0 million in 2022, then soared by 33.01% to $137.0 million in 2023, then decreased by 5.04% to $130.1 million in 2024, then increased by 7.61% to $140.0 million in 2025.
- Its EBIAT stands at $140.0 million for Q3 2025, versus $131.8 million for Q2 2025 and $89.8 million for Q1 2025.